Edesa Biotech (EDSA) has released an update.
Edesa Biotech, a biopharmaceutical company, will attend the Barclays 26th Annual Global Healthcare Conference in Florida from March 12-14, 2024, showcasing their progress in developing treatments for immuno-inflammatory diseases. Their leading drug candidate EB05 is being tested for Acute Respiratory Distress Syndrome, while other treatments are in the pipeline for conditions like vitiligo and chronic Allergic Contact Dermatitis. Investors and attendees can schedule meetings with Edesa’s management through the conference or by reaching out to the company directly.
For further insights into EDSA stock, check out TipRanks’ Stock Analysis page.
